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Pyrophosphate, which may be deficient in advanced renal
failure, is a potent inhibitor of vascular calcification. To
explore its use as a potential therapeutic, we injected
exogenous pyrophosphate subcutaneously or
intraperitoneally in normal rats and found that their plasma
pyrophosphate concentrations peaked within 15min. There
was a single exponential decay with a half-life of 33min.
The kinetics were indistinguishable between the two routes
of administration or in anephric rats. The effect of daily
intraperitoneal pyrophosphate injections on uremic vascular
calcification was then tested in rats fed a high-phosphate diet
containing adenine for 28 days to induce uremia. Although
the incidence of aortic calcification varied and was not
altered by pyrophosphate, the calcium content of calcified
aortas was significantly reduced by 70%. Studies were
repeated in uremic rats given calcitriol to produce more
consistent aortic calcification and treated with sodium
pyrophosphate delivered intraperitoneally in a larger volume
of glucose-containing solution to prolong plasma
pyrophosphate levels. This maneuver significantly reduced
both the incidence and amount of calcification. Quantitative
histomorphometry of bone samples after double-labeling
with calcein indicated that there was no effect of
pyrophosphate on the rates of bone formation or
mineralization. Thus, exogenous pyrophosphate can inhibit
uremic vascular calcification without producing adverse
effects on bone.
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Pyrophosphate (PPi) is a potent inhibitor of calcium
crystallization that is present in body fluids at concentrations
sufficient to prevent hydroxyapatite formation in vitro,1–3
suggesting that it may function as an endogenous inhibitor of
calcification. In particular, production of PPi by smooth
muscle may be an important defense against medial vascular
calcification. Rat aortas do not calcify in vitro unless the PPi
produced by the vessels is removed.4 Furthermore, humans
lacking ectonucleotide pyrophosphorylase1 (Enpp1), the
enzyme that synthesizes extracellular PPi, develop severe
medial arterial calcification at an early age.5–7
Recent data suggest that PPi deficiency may contribute to
the increased incidence of medial vascular calcification in
advanced kidney disease. Levels of PPi are reduced in
hemodialysis patients,8 and correlate inversely with the level
of vascular calcification in patients with advanced chronic
kidney disease.9 Hydrolysis of PPi is increased in aortas from
uremic rats because of upregulation of alkaline phospha-
tase,10 providing a mechanism for vascular deficiency of PPi.
Therefore, the data suggest that exogenous PPi may be useful
in treating or preventing uremic vascular calcification.
Studies conducted more than four decades ago showed
that subcutaneously administered PPi inhibited medial
arterial calcification in vitamin D-toxic rats.11 However, large
doses were required and the treatment resulted in marked
skin necrosis. Nonhydrolyzable analogs of PPi, such as
bisphosphonates, were subsequently shown to inhibit vas-
cular calcification in the same animal model, but at much
lower doses.3 More recently, bisphosphonates have been
shown to prevent aortic calcification in uremic rats.12,13 One
potential problem with this therapy, however, is inhibition of
bone formation. The high levels of tissue-nonspecific alkaline
phosphatase (TNAP) in bone serve to remove PPi and allow
bone formation to occur in the face of inhibitory circulating
PPi concentrations.14 This is the basis for the skeletal abnor-
malities in hypophosphatasia, where TNAP is deficient.15
However, TNAP would not protect bone from the non-
hydrolyzable bisphosphonates and, accordingly, the doses of
bisphosphonates that inhibit vascular calcification in uremic
rats also inhibit bone formation.13
Based on these previous results, we reasoned that
exogenous PPi might inhibit uremic vascular calcification
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without adversely affecting bone. Therefore, we explored the
therapeutic potential of PPi in uremic vascular calcification
by examining both its pharmacokinetics and its effects on
aortic calcification and bone formation in a model of medial
arterial calcification in uremic rats.
RESULTS
Pharmacokinetics
Initial studies were performed in three rats using a single
subcutaneous injection of 80 mmol/kg of PPi containing
tracer 32PPi. At 15min, 51.9±3.5% of the radioactivity in the
plasma was in the form of orthophosphate and this increased
to 91.4±0.8% at 120min, indicating rapid hydrolysis of PPi.
Plasma 32PPi peaked at 15min and decreased exponentially
thereafter (Figure 1a). The r2 for the linear regression of the
logarithmically transformed data ranged from 0.95 to 0.98,
indicating a single-exponential decline and yielded a half-life
of 31.4±1.4min. Extrapolation to the ordinate yielded an
apparent volume of distribution of 4.1±0.5 l/kg. In an
additional study performed with both renal arteries and veins
occluded to determine the renal contribution to PPi clear-
ance, the half-life was 35min (not shown). Similar results
were obtained after intraperitoneal injection (Figure 1b),
with a half-life of 34.1±2.6min. However, the peak concen-
tration as a fraction of the dose (0.336 and 0.340mM/mmol/kg)
was greater than after subcutaneous injection (0.196±0.041
mM/mmol/kg), suggesting better delivery by the intraperitoneal
route. With either route, the half-life was not affected by the
dose (shown in Figure 1b). Oral administration was not
attempted because of rapid PPi hydrolysis in the intestinal
tract.11
Effect on vascular calcification
To determine whether PPi administration reduces uremic
vascular calcification, rats fed a high-phosphate diet contain-
ing adenine first underwent daily subcutaneous injection of
sodium PPi. However, this route resulted in subcutaneous
nodules and was therefore abandoned. In contrast, daily
intraperitoneal injection of sodium PPi in a volume of
5ml/kg appeared to be well tolerated and was therefore used
to test our hypothesis. Body weights and plasma chemistries
of these rats at the time of killing are presented in Table 1.
There was no mortality in the control group. One rat treated
with 160 mmol/kg/day died at 10 days (13% mortality).
Two rats treated with 80 mmol/kg/day died at 11 and 27 days
(25% mortality). The aorta from the latter rat was included
in the analysis and was not calcified. PPi treatment did not
alter animal weight or the plasma concentrations of calcium
and phosphorus. Plasma alkaline phosphatase activity was
slightly reduced in the rats treated with the lower dose of PPi
but not the higher dose. The urea concentration was slightly
higher in the rats treated with the higher dose of PPi but
this was not observed in subsequent studies at the same dose
(see below), and there were no other signs (weight loss,
physical appearance) that these rats were more uremic. There
was no correlation between any plasma parameter or the
adenine dose and aortic calcium content.
In rats fed a normal diet, aortic calcium content was
20±3 nmol/mg (n¼ 22). A calcium content of 53 nmol/mg,
which is 3 s.d. above that in normal rats, was employed
a priori to define pathological calcification. As shown in
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Figure 1 |Change in plasma pyrophosphate (PPi)
concentration after injection of PPi containing tracer [32P]PPi.
(a) Single subcutaneous injection of 80 mmol/kg sodium PPi in
three different rats. (b) Single intraperitoneal injections of
0.026 mmol/kg (solid symbols) or 2.6mmol/kg (open symbols)
sodium PPi in a volume of 5ml/kg. The increment in plasma PPi
concentration was calculated from the specific activity of the
injected 32PPi.
Table 1 | Plasma chemistries in adenine-fed rats receiving
daily intraperitoneal injections of NaPPi in 10ml/kg
PPi dose, lmol/kg/day
Baseline 0 (n=15) 80 (n=6) 160 (n=7)
Body weight (g) 324±1 223±6 220±10 230±5
Urea (mmol/l) 10.2±0.5 23±2 24±3 36±6*
Calcium (mmol/l) 1.96±0.04 1.79±0.10 1.62±0.09 1.99±0.13
Phosphorus (mmol/l) 1.4±0.1 6.9±0.8 6.7±0.4 6.7±0.6
Alkaline phosphatase (IU/l) NA 76.3±1.2 54.8±1.5* 80.0±3.9
Abbreviations: NA, not assayed; NaPPi, sodium PPi; PPi, pyrophosphate.
*Po0.05.
Baseline chemistries were obtained from six rats of similar age fed normal rat chow
(23% protein).
Results are means±s.e.m.
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Figure 2, aortic calcification is variable in this model and only
developed in 40% of vehicle-treated rats. The lowest calcium
content that met the definition of pathological calcification as
outlined above was 235 nmol/mg, indicating a clear distinc-
tion between calcified and noncalcified aortas. The incidence
of aortic calcification was decreased by PPi at 160 mmol/kg
(29 vs 40%), but the difference was not significant. Although
there was a dose-dependent decrease in the calcium content
of the calcified aortas up to 74% (1898±466 vs 965±319 vs
489±205 nmol/mg), the difference was not significant
because of the variability in calcification.
To better demonstrate the effect of PPi, changes were
made in order to prolong the effect of PPi and to reduce the
variability in calcification. To slow the absorption of PPi
from the peritoneum, the volume of fluid was increased to
40ml/kg and glucose was added. As shown in Figure 3, this
resulted in a threefold increase in the plasma PPi level, and
levels remained elevated for B240min. To reduce the
variability in aortic calcification, uremic rats were given
40 ng/kg of calcitriol three times per week by subcutaneous
injection. This resulted in extensive aortic calcification in all
animals (Figure 4), but did not increase aortic calcium
content in nonuremic rats, even at the substantially higher
dose of 100 ng/kg (33.3±4.3 nmol/kg; n¼ 6), indicating that
this effect is specific for uremia.
Two PPi solutions were tested in the studies shown in
Figure 4, 0.8 and 4mmol/l, both injected daily at 40ml/kg,
resulting in doses of 32 and 160 mmol/kg/day. The
higher dose significantly reduced aortic calcium content
(1040±762 nmol/mg vs 4773þ 565 nmol/mg, Po0.005) and
the incidence of calcification (67 vs 100%, Po0.05).
The lower dose did not alter calcification (4744±418nmol/
mg). Body weight (276þ 10 vs 271þ 14 g), plasma urea (25þ 5
vs 25þ 3mmol/l), plasma calcium (1.50þ 0.06 vs 1.58þ 0.07
mmol/l), and plasma phosphorus (6.7þ 0.3 vs 6.5þ 0.3mmol/l)
did not differ between rats treated with 160mmol/kg and vehicle-
treated rats. Plasma PPi levels at the time of killing (24h after the
last peritoneal infusion of PPi) were the same in control rats
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Figure 2 | Effect of pyrophosphate (PPi) on aortic calcium
content in uremic rats. Rats were fed a diet consisting of 2.5%
protein, 1.06% phosphorus, 0.92% calcium, and 0.75% adenine for
4 weeks and received sodium PPi in Hank’s buffered saline or
saline alone by daily intraperitoneal injection of 5ml/kg. Each
point represents a single animal.
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Figure 3 |Plasma pyrophosphate (PPi) concentration after
single intraperitoneal injections of 160 lmol/kg sodium PPi in
a volume of 40ml/kg. Results are means±s.e.m. of four animals.
*Po0.01, **Po0.001, #Po0.05 vs baseline.
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Figure 4 | Effect of peritoneal infusion of pyrophosphate (PPi)
on uremic vascular calcification. Rats were fed a diet consisting
of 2.5% protein, 1.06% phosphorus, 0.92% calcium, and 0.75%
adenine for 4 weeks and given calcitriol 40 ng/kg by
subcutaneous injection 3 times per week. PPi was infused daily
through a peritoneal catheter in a volume of 40ml/kg. Each point
represents a single animal. *Po0.005 vs control.
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(5.5±0.4mM) and rats treated with the higher dose of PPi
(5.3±0.7mM), indicating that there was no accumulation of PPi
in the plasma over the course of the experiment.
Effect on bone
Quantitative histomorphometric analysis was performed
on femurs from uremic rats (receiving or not receiving
calcitriol) treated with or without PPi (high dose only), and
are shown in Table 2. For comparison, data from pair-fed
nonuremic rats obtained in a previous study are also shown.
All parameters of bone formation were greatly increased in
uremic rats, but were unaffected by PPi treatment. Osteo-
clastic parameters were also unchanged by PPi treatment
(data not shown).
Other effects
There was no mortality in the second set of studies and there
was no difference in the appearance or behavior of the PPi-
treated rats. Examination of the knee joint revealed no crystal
deposition in rats treated with PPi (not shown). Histology of
the abdominal organs revealed a chronic inflammation of the
peritoneum covering the diaphragm in low- and high-dose
groups (Figure 5) and fibrosis of the splenic capsule and
chronic inflammation involving the mesentery attached to
the spleen in the high-dose group. In general, the severity of
the peritoneal reaction on the diaphragm was marked in
rats given 4mmol/l PPi and only mild in rats receiving
0.8mmol/l. A mild inflammatory response was also observed
in the placebo group, presumably a response to the surgery,
the presence of the peritoneal catheter, or exposure to the
vehicle. No animal showed overt signs of peritonitis.
DISCUSSION
This study demonstrates that exogenous PPi can substantially
inhibit vascular calcification in uremic rats. This action is
presumably because of an increase in the concentration of
PPi in the vessel wall, which directly inhibits hydroxyapatite
formation. Tissue levels are controlled by local production
and hydrolysis as well as diffusion from the blood. We have
previously shown that plasma levels of PPi are reduced in
hemodialysis patients8 and that PPi hydrolysis is increased in
vessels from uremic rats.10 Although the effect of uremia on
extracellular PPi production in the vessel wall is unknown,
these data suggest a reduction in extracellular PPi levels in
uremic vessels. Owing to the short half-life of PPi in plasma,
only transient increases in the concentration of plasma PPi
occurred with treatment, and it is possible that the increases
in tissue PPi were similarly transient. However, the data show
that a 4 h increase in PPi levels with a peak tripling was
sufficient to substantially inhibit calcification. This suggests
that only intermittent correction of PPi deficiency can
prevent calcification.
As PPi could potentially inhibit any hydroxyapatite
formation, effects on normally calcified tissues such as bone
need to be considered. Despite the robust inhibition of
vascular calcification in uremic rats, there was no effect on
any parameters of bone formation. This selective action of
PPi is probably explained by the high levels of TNAP in bone.
This ectoenzyme hydrolyzes PPi and enables mineralization
to occur in the face of circulating PPi levels that can inhibit
hydroxyapatite formation.14 The inhibition of bone formation
that we previously observed with doses of bisphosphonates
sufficient to inhibit uremic vascular calcification13 can prob-
ably be explained by the fact that bisphosphonates are not
hydrolyzed by TNAP and can thus directly inhibit bone
mineralization. Another explanation for the selective effect
of PPi is the immediate proximity of the vascular wall to
circulating PPi compared with bone tissue.
There was a significantly greater plasma urea concentra-
tion with the highest PPi dose in the initial study. The fact
that this group did not have a reduction in adenine dose
compared with the other groups (see Materials and Methods)
could have contributed. However, the animals did not show
other signs of increased uremia, and plasma urea was not
increased in the second set of studies despite the same dose of
adenine. There was no articular crystal deposition indicative
of calcium PPi deposition disease, suggesting that arthritis
will not be a side effect of PPi treatment. An inflammatory
reaction was present in the peritoneum, indicating that this
dose and frequency of PPi is not feasible for long-term
intraperitoneal delivery.
Our initial studies were hampered by the variability of
vascular calcification in the adenine, high-phosphate diet
model, often witho50% of rats developing any calcification.
Table 2 | Parameters of bone formation in normal rats and in adenine-fed rats treated with or without 160 lmol PPi/kg/day
Uremic
No calcitriol Calcitriol
Normal (6) Control (7) PPi (7) Control (6) PPi (6)
Bone volume (% of total) 12.5±1.6 14.2±2.5 15.8±1.6 14.4±1.1 11.4±0.8
Osteoblasts (no. per 100mm) 29±2 494±198 176±82 453±110 399±278
Osteoblast surface 0.39±0.04 6.2±2.2 2.5±1.1 5.6±1.3 5.3±3.3
Osteoid thickness (mm) 3.6±0.5 4.6±0.9 4.4±1.1 4.6±0.9 3.5±0.3
Mineral apposition (mm/day) 2.0±0.3 5.7±0.6 5.5±0.6 6.8±0.5 6.8±0.6
Bone formation (mm3/cm2/year) 9.9±1.9 24.9±6.3 21.9±5.2 43.2±8.5 45.3±6.2
Abbreviation: PPi, pyrophosphate.
None of the differences between control and PPi-treated rats were significant by Mann–Whitney U-test.
Parentheses indicate the number of animals in each group.
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This has also been observed by other investigators, and the
mechanism responsible for this variability is unknown.12,16
Lowering the protein content of the diet, which eliminated
this variability in a previous study,12 was not effective in this
study, but treatment with calcitriol resulted in aortic
calcification in all animals and increased the overall degree
of calcification. This effect of calcitriol on uremic calcifica-
tion has been observed in other studies and with other
models,17–19 but usually with higher doses We also found
that treatment of normal rats on a high-phosphate diet
with a 2.5-fold higher dose of calcitriol did not increase
aortic calcium content, indicating that calcitriol was acting
synergistically with the renal failure.
This study indicates that PPi may be a useful therapy for
uremic vascular calcification. Inhibition of calcification was
achieved with only small, transient daily increases in plasma
PPi that did not produce any adverse effects on bone.
Additional studies will be required to determine the optimal
dosing and route of administration and whether PPi can
reverse existing vascular calcification.
MATERIALS AND METHODS
Plasma PPi kinetics
Male rats (230–400 g) were anesthetized with isoflurane for the
duration of these studies. Polyethylene tubing was placed in the
carotid artery and kept patent with heparinized saline. After
injection of 32PPi, 200ml samples of blood were drawn into
heparized tubes and centrifuged to collect plasma. Plasma was
combined with an equal volume of 10% trichloroacetic acid and
centrifuged again. Orthophosphate was extracted as previously
described10 using 1 volume of supernatant, 10 volumes of 30mmol/l
ammonium molybdate in 0.75 M sulfuric acid, and 20 volumes of
isobutanol/petroleum ether (4:1). Radioactivity in the organic phase
was counted and radioactivity remaining in the aqueous phase was
assumed to be PPi. The change in plasma PPi concentration was
calculated from the specific activity of the injected PPi. In some
experiments, unlabeled PPi was injected and PPi was assayed
directly in the plasma.
Aortic calcification in uremic rats
Chronic renal failure was produced by feeding adenine to rats.20,21
Male Sprague-Dawley rats were obtained from Charles River
Laboratories (Wilmington, MA) and fed a standard rodent diet
until body weight exceeded 300 g. Rats were then fed a 2.5% protein
diet (Harlan Teklad, Madison, WI), which enhances vascular
calcification,12 supplemented with neutral sodium phosphate. This
diet contained 1.06% phosphorus and 0.92% calcium. The adenine
content was 0.75% and was reduced to 0.5% for rats that had a rapid
rate of weight loss. This occurred after 10 days in half the rats in the
control group and all the rats in the 80 mmol/kg group in the studies
shown in Figure 2, and after 21 days in 3 rats each in the control
group and the 32 mmol/kg group in the studies in Figure 4. For some
experiments, calcitriol (Calcitriol Injection, American Regent
Shirley, NY) was given subcutaneously at a dose of 40 ng/kg every
Monday, Wednesday, and Friday, concomitant with the adenine diet.
Calcein (2mg in 2ml Hank’s solution) was injected intraperitoneally
on days 20 and 25 to label bone. Rats were killed after 28 days and
aortas were perfused with saline, harvested, and cleaned. All
protocols were approved by the Institutional Animal Care and Use
Committee.
Intraperitoneal PPi therapy
In initial studies, sodium PPi was injected daily in 5ml/kg of a
buffered saline solution and was started simultaneously with the
adenine diet. Larger volumes were used in subsequent studies and
required peritoneal catheters. Three days before beginning adenine
a
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Figure 5 |Histology of the diaphragm and parietal peritoneum
in uremic rats given sodium pyrophosphate (PPi) by
intraperitoneal injection. (a) Vehicle; (b) 0.8mmol/l PPi;
(c) and 4mmol/l PPi. Hematoxylin and eosin staining.
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treatment, peritoneal catheters were placed through a midline
abdominal incision and tunneled subcutaneously to a subcutaneous
port implanted behind the neck (Clearport; Access Technologies,
Skokie, IL). Sodium PPi in a sterile, glucose-containing, buffered
saline solution was injected daily through the skin into the
subcutaneous port in a volume of 40ml/kg, starting on day 8 of
the adenine diet. Control rats received the same solution without PPi.
Biochemical assays
After drying and weighing, the entire aortas were extracted overnight
in 1M HCl, and calcium in the extract was measured colorimetrically
by the cresolphthalein method.22 Plasma urea was measured
colorimetrically by the urease–glutamate dehydrogenase method
(Sigma-Aldrich, St Louis, MO), plasma phosphate was measured
colorimetrically by the molybdate method,23 and plasma calcium was
measured by the cresolpthalein method.22 Plasma PPi was measured
enzymatically as previously described,8 with modifications. Plasma
was diluted 1:4 with PPi-free water, and 20ml samples were incubated
with 100ml of assay solution containing 4mM uridine dipho-
sphoglucose (UDPG), tracer UDP[14C]glucose, 0.3 units/ml UDPG
pyrophorylase (type X from baker’s yeast), 2 units/ml phosphogluco-
mutase (from rabbit muscle), 0.5 units/ml glucose-6-phosphate
dehydrogenase (type XV from baker’s yeast), and 10mM NADP in a
buffer of 90mmol/l KCl, 5mmol/l MgCl, and 70mmol/l Tris, pH 7.6.
After 30min at 37 1C, the unreacted UDP[14C]glucose was removed
by charcoal precipitation and radioactivity in the supernatant was
counted. The concentration of PPi was calculated from the difference
between assays performed with and without UDPG pyrophosphory-
lase. PPi-free water and buffer were prepared by elution through a
column of hydroxyapatite.
Bone histomorphometry
After killing, one femur was removed, cleaned of attached tissue,
and placed in absolute ethanol. After dehydration, samples were
embedded in methylmethacrylate and eight sections were cut serially
at 4-mm thickness with a heavy-duty microtome. This thickness
allows analysis of the same histological features in slides prepared for
light and fluorescent microscopy. Every other section was stained
with the modified Masson-Goldner trichrome technique while the
other sections were reserved for fluorescence microscopy. Static and
dynamic parameters of bone structure, formation, and resorption
were measured at a standardized site below the growth plate using a
semiautomatic method.24,25
Reagents
32PPi was obtained from Perkin Elmer-NEN (Waltham, MA). Unless
otherwise indicated, all other reagents were obtained from Sigma-
Aldrich.
Statistics
Differences between control and treatment groups were determined
by one-way analysis of variance or Mann–Whitney U-test for
nonparametric data, with correction for multiple comparisons.
Comparison of the incidence of calcification was by w2 testing.
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